Main findings
We detected no difference in the rates of congenital malformations,
neonatal infection, low birth weight, small for gestational age,
miscarriage or pre-eclampsia with the use of biologics in pregnancy. The
rates of preterm delivery were not statistically different between the
treated and the disease matched groups but there was a statistical
difference noted between the treated and disease free group, possibly
pointing towards the disease process being a factor. Too few studies
examined serious maternal infection as an outcome to be concluded upon.
These findings may offer significant reassurance to both clinicians and
patients alike in continuing these targeted agents during pregnancy.